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Summary - A series of N-Aroyl-cyclohexyl- and cyclohexenylamides 3- or 4-methylsubstituted were syn-
t~es.i~ and evaluated for their anti-inflammatoIY and an:ugesic potencies. and gastrointestinal initation 
liabllity. One compound, N-benzoyI4-methyl-cyclohexylrumde 6a. possessed an anti-inflammatory activity 
comparable to that of indomethacin. 
INTRODUCTION 
In previous studies interesting anti-Inflammatory 
and anal§esic activities were found in some 
indole1,l.3, (1) and cycloalkane or cycloalkeneS•6 
(2 and 3) 1-(N-acyl)amino derivatives (Figure 1). 
970CH~ ~ ~ Ni fl tti H I I 
R R R 
1 2 3 
n = 1,2,3 
R = p-CI-CeH ... CO; 3.4.5-(CtilQP-CeHrCO; p-C1-<6H.-CH=CH-CO 
3.4~Ct\P>-CeH2-CH=CH-CO:HOOC-CH=CH-CO 
R1 = H; Cl-b; OH; Cl 
R2= H;Ctb 
~ = single bond; double bond 
Fig. I 
Such activities were strongly influenced by the 
nature of the acyl moietY bound to the amino 
group and, in case of compounds 2 and 3, by the 
substituents on cyc10alkane or cycloalkene ring, 
In order to acquire new insights on structure-acti-
vitY relationships of this new class of compounds, 
in t~e present paper We describe the synthesis and 
the phannacological evaluation of new derivatives 
4a-£, 5a-£ and 6a-£ (Figure 2), in which, respect to 
compounds of general structure 3, the substituent 
on the ring, the methyl moiety, was shifted from 
position 2 to position 3 or 4, and a double bond 
between carbons 2-3 of the cycloalkanering, in the 
case of compounds 4a-{. was also introduced. 
(*) To whom correspondence should be addressed. 
Fig. 2 
4a-f Sa-f 
a R = p-Cl-4fi4-CO-
b R = 3.4.5-(Ct-bOh-CsH2"CO-
C R = CsHs-CH=CH-CO-
d R = p-CI-CsH4"CH=CH-CO-
6a-f 
e R = 3,4.5-(Ct-hOh-C6Hz-CH=CH-Ca-
f R = 3.4-(CH;PV-Cs~H=CH-Ca-
CHEMISTRY 
The preparation of amides 4a-{, 5a-f, and 6a-£ 
was pedonned by stirring the suitable amino 
compound 6a-c with an excess of the appropriate 
acyl chloride, in benzene at room temperature, in 
the presence of triethylamine (Scheme I), 
The characteristics of compounds 4a-£, 5a-f, and 
6a-f are described in Table I. 
The structure of the obtained compounds was 
yenerally supported by JR, GC-MS (Table 11), and 
H NMR (Table ITl) spectra. 
Starting amines 9a-c were prepared reducing the 
ketoximes of 3-methyl-cyclohexenone, 3-methyl-, 
and 4-methyl- cyclohexanone 8a-c with sodium in 
anhydrous ethano}7·8, respectively. 
The oxime 8a was prepared by the direct action 
of hydroxylamine hydrochloride on the 3-methyl-
cic1ohexenone 7a according to Adams9, 
The ketone 7a was obtained accordin§ to an 
experimental procedure already described} . 
On the contrary, the oximes 8b,c were prepared 
according to Lachman11 starting from 3-methyl-
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and 4-methyl-cyclohexanone 7b,e which were 
commercially available. 
In Table IV the characteristics of compounds 7a, 
8a-e and 9a-c are described. 
TABLE I - Characteristic data of compounds 4a-f, 
Sa-fand 6a-f 
COrnp. Formula M.W. M.p.re) Yield Method of 
% purification 
4a C,.H,eNOCI 249 195-197 45. B 
4b C17H23NO. 305 168-170 49 G 
4c C,eti,gNO 241 131~133 77 A 
4d C,sH,SNOCI 275 179-182 45 H 
4e C,.H~O. 331 169-172 52 C 
4f CI1H,gNQ, 285 151-153 96 C-E 
Sa C,.H,aNOCr 251 1715-178 90 E 
5b Cl1H~O. 307 187-189 96 E 
Se C18H21 NO 243 144-145 65 D-F 
5d C,eH~OCI 277 200-202 79 C-E 
Se C'IH~04 277 189-191 68 C-E 
Sf C'7~,N03 287 161-163 66 F 
6a C,.H,sNOCI 251 235-236 98 C 
ab C17H~O. 307 209-211 67 E 
6c C"HZ1 NO 243 199-201 73 G 
6d C,a~NOCI 277 252-253 89 C-E 
Se C,.HvNO. 333 220-222 85 E 
6f C17H21N~ 287 229-231 42 E 
.. -. 
A. B) Chromatography (siHca gel column, eluant: benzene-
acetone 8/2 and 9/1). C) Flash chromatography (silica gel col-
umn, eluant: benzene-acetone 8/2). D) Flash chromatography 
(silica gel column, eluant: petroleum ether- ethyl acetate 7/3). 
E) Crystallization (ethanol). F) Crystallization (ethanol/water). 
G) Crystallization (methanol). H) Ana}yzed as pure compound. 
Among the acyi chlorides, most of them were 
commercially available, except 3,4-methylene-
dioxycinnamoyl chloride which was pre~ared 
according to the procedure described by Koo 3. 
PHARMACOLOGY 
All compounds 4a-f, Sa·f and 6a·f were sub-
jected to a series of in vivo tests in order to evalu-
ate their pharmacological activity. The anti-
inflammatory activity was studied by means of the 
carrageenan rat paw edema assay, whereas the 
acetic acid writhing test was used to assess the 
analgesic activity in mice. Higher doses were 
administered to rats in order to study the irritative 
and ulcerogenic action on the mucosa of the 
stomach and small intestine up to the distal 
ileum. Indomethacin was included in all tests as 
reference drug. 
RESULTS AND DISCUSSION 
As can be noted (Table V), compounds 4b,e and 
6a,b showed an interesting and dose-depending 
anti-inflammatory activity, compounds Sb,d,e and 
6c showed a lower activity, whereas all the other 
compounds resulted moderately or poorly active. 
It is worth to note that 6a at 40 mglkg was signif-
icantly more active than indomethacin at 5 mg/kg. 
These results were substantially confinned by 
acetic acid writhing test. used to assess the anal-
gesic activity (Table VI). 
In fact, best results were shown by compounds 
4b,e and 6a, and also Sb,d and 6c showed a sig-
nificant activity in this test. The main exceptions 
were 6b, that resulted almost lacking analgesic 
activity, and compounds 4a and 6d, that on the 
contrary showed a moderate analgesic activity, 
although they were almost inactive in rat paw 
edema test. 
Concerning the ulcerogenic potency (Table VII), 
all compounds showed to be much less ulcero-
genic than Indomethacin (at 5 mg/kg) especially in 
view of the severe dose used (100 mg/kg). Anyway 
it does not always correspond to the anti-inflam-
matory and/or analgesic effect. In fact, the ulcero-
genic potency of the most active compounds (4b,e 
and 6a) was not significantly different from the 
potency of compounds that were completely lack-
ing in anti-inflammatory and analgesic activities. 
These pharmacological results allow us to draw 
some preliminary conclusions on structure-activity 
relationships. . 
As regards the acyl moiety, the anti-inflamma-
tory and analgesic activities were mainly linked to 
the 4-chlorobenzoyl (6a) and trimetoxybenzoyl 
residues (4b, Sb, 6b). Among the derivatives bear-
ing an (un)substituted cynnamoyl moiety, best 
results were obtained by compounds without sub-
stituents on the phenyl ring (4c, 6c), although the 
activity of some of the others was not negligible 
(Sd,6d). 
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TABLE If - GC-MASS spectra of compounds 4a-f. 5a-f and 6a-f 
GC-MS IR 
Products t, Most Important Fragments (Wiz) vN-H vC--o 
(min) (cm-', (cm", 
4a 19.4 249: (M ); 156: [p-CI-C6H4-CO-NHzl; 138: 3280 1640 
I r. ...,;.. .r..Ol; 111: rC7H,~1. 
'b 7.2 305: (M); 211: (C~O)3,.CsHrCO-NH:zl; 3260 1650 195:[(CH;O)3"C~i'b-Coi; 110:-[C?H,3Nl. 
<Cc 21.4 241: (M ); 146: (C6H5-CH=CH-CO-NH2]; 131: ICe~ 3270 1625 
CH=CH-COJ; 103: rCeHs-CH=CH1; 110:' rCrH,;Ni. 
'd 15.9 275: (M );.182: [p-CI-CsH4-CH=CH-CO-NHzj; 165: 3250 1640 
Ip-CI-CsH..-cH=CH-CO); 137: [p-CI-CsH .. CH=CH]; 
110: LC~13Nl 
.. 18.9 331: (M ); 236: [(CHJOkCsHiCH:;CH-CO-NH:z); 3260 1650 
221: [(CHJOh-CsHrCH=CH-CO); 193: [(C~O)T 
• ~H=cHi; 110: rC7H,~1. 
41 17.9 285: (M); 190: (3,4-(CH202)-CsHrCH=CH-CO-NH21; 3280 1620 
175: (3,4-(C~0:!)-Ci;H3"CH:;CH-CO}; 147: [3;4-
I {CH,o;)-.CRHrCH=CH1; 110: rC..H,i;1. 
Sa 12.3 251: (M ); 156: [p-CI-CsH .. CO-NHz]; 139: (p-CI- 3280 1620 
i CsH .. CO); 111: (C?HI1N). 
5b 17.9 307: (M ); 211: (CH30h-CsH:z-CO-NH21; 195: 
I f(CH,.O)~HrC01; 112: rC7H,o;Nl 
3260 1645 
Se 15.4 243: (M ); 147: (Ce~-CH=CH-CO-NHz]; 131: ICe~ 
C!-I=CH-COl; 103:-rCsHs-CH=CH1; 112:' (C7H,;Ni. 
3270 1620 
5d 15.8 277: (M ); 180: [p-CI-CsH4-CH=CH-CO-NHz];165: 3230 1640 




Se 18.6 333: (M ); 236: [(CH30kCsH:z-CH=CH-CO-NH21; 3270 1645 
221; [(CH30h-CsH:z-CH=CH-CO); 193: {(CH30h-
G,;H;cH=CH1; 112: (CrH,~l. 
51 17.6 287: CM ); 190: [3.4-(CH2~C6HrCH=CH-CO-NH21; 3270 1640 




6a 7.1 251: (M ); 156: [p-CI-CsHrCO-NHzJ; 139: (p-CI-
CsH..-cO); 112: 'iC7H1sN]. 3260 1640 
6b 16.4 307: (M ); 211: [(CHPh-CeHrCO-N~); 195: 
'T<CH:.O'''' LI;'Ol: 112: rCrH'5Nl. 
3240 1650 
6c 8.6 243: (M); ~t:7: (Cs~~=CH-CO-N~l; 131:1!~ 3280 1620 
CH=CH-CO; 103: -CH=CH1; 112: r~Hl . 
6d 17.4 277: (M); 180: [p-CI-CsH .. CH=CH-CO-NHzJ; 165: 3280 1630 
[p-CI-CsH.rCH=CH-CO}; 137: [p-C1-CsH.-GH=CH}; 
112: rC7H;5N1. . 
6e 13.6 333: (M ); 236: [(CH~kCeHrCH=CH~CO-NH21; 3260 1650 
221: [(CHJO)~H:z-CH=CH-COJ; 193: [(CHlOk 
C6~H=CH1; 112: (C7H'5Nl. 
61 11.9 287: (M ); 190: r3,4-{C~~CH=CH-CQ..NHz]; 3280 1640 
175: [3.4-(C~H=CH-CO}; 147: 13,4-I (CH2Ch)-CsH;CH=CHJ; 112: TC7H1;.n. 
Concenling the substituted cycloaliphatic 
moiety. it is not easy to establish the best position 
of the methyl group on the ring. In fact some evi· 
dences seem to indicate position 4: for example, in 
case of 6a, shifting the methyl group to position 3 
led to compounds with diminished activity (4a 
and5a). In other cases the introduction of a dou-
ble bond between position 2 and 3 avoids this 
decrease in activity. For example. 5b was less 
active than 6b (at least in rat paw edema test), 
but 4b had the same or even a greater phannaco-
logical potency compared to 6b; besides, 4e was 
significantly more active than 6c and 5e in both 
pharmacological tests. 
detailed pharmacological characterization is requi-
red to establish their action mechanism. 
In conclusion, this series of amides provide 
information for the development of new interest-
ing and selective anti-inflammatory and analgesic 
compounds with low ulcerogenic activity. A more 
Further studies concerning structure activity 
relationship are planned to establish definitively 
the ideal position, bulk and chemical nature of the 
substituents on the cycloaliphatic ring. . 
EXPERIMENTAL 
A) CHEMISTRY 
Precoated silica gel Merck 60 F254 plates were used for 
thin layer chromatography: detection of components was 
made by UV light (254 nm) and/or treatment with iodine 
vapors~ Chromatographic and flash-chromatographic separa-
tions were performed in columns packed with silica gel 60 
(Merck 70-230 mesh ASTM) and in columns packed with sil-
ica gel 60 (Merck 230-400 mesh ASTM), respectively. Melting 
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TABLE III - IH NMR spectra of compounds 4a-f. 5a-f and 6a-f 
Comp. appm 
4. 0.9-0.94: (d. 3H CB,)~ 0.75-2.1: (m. 6H cydoal.)~ 3.85-4: (m. IH CH~N)~ 5.4: 
lis, 1H CB-); 5.95-6.05: Cd 1H NII); 7.31-7.75: (m. 4H al"Olllatics). 
4b 0.8-2.1: (m. 7H cydoaL); 0.9..0.95: (d. 38 CB,,); 3.87: (s, 9H 30CJ1J); 3.8-4: 
I (m. lH CH-N); 5.24: (s, IH CB=); 6-6.1: (d. IH N_H); 6.99: (s, 2Haromatia). 
ok 0.9..0.94: (d. 3H ~); 0.75-2.1: (m. 6H cycloaL); 3.85-4: (m. lH rn-N); 5.38: 
(s, lH CH""); 5.75-S.8S: (d. IH NB); 6.3-6.4: (d.1H Co-cu. .. ); 7.6-7.7: 7.3-
7.55~ SH aromatics)~7.6-7.7: (d IH Ph-CR-). 
4d 0.88..0.91: (d. 3H CIi.s); 0.75-2.1: (m, 6H cycloaL); 3.75-3~9: (m, 1H CH-N); 
5.38: (s, lH CROIa); 5.75-5.85: (d. 1H NB); 6.35-6.4: (d. 1H CO-CB); 7.25-7.45: 
(m. 4H aromatks); 7.53-7,6: <d lH, Ph-CB=). . 
4e 0.88-0.91: (d, 3H CBl ); 0.75-2.1: (m. 6H ~ydoaL);3.85: (s,. 9H 3OCU,); 3.8-
3.91~ (m, IH CH-N); 5.36: (s, 1H CB=); 5.6-5.65: (d, 1H NB); 6.25-6.3: (d. IH 
CO-CB=); 6.7: (s. 2H aromatics)~ 7.45-7.5: (d, 1H Ph-CH-). 
4f 0.87-0.9: (d,3H ~); 0~72-2.05: (m. 6H cycloaL);3.8-3.9S: (m, 1H CH-N); 
5.36: (s. 1H CH=); 5.65-5.75: (d. lH NB)~5.96: (s. 2H o-cu.rO); 6.18-6.23: (d, 
IH co-eD=); 6.7-7: (m. 3H aromatics): 7.5-7.54: (d, 1H Pb-CB). 
Sa 0.88-0.95: (d, 3H CB.s); 0.65-2.1: (m. 9H c:ydoaL); 3.8-4: (m. 1H CH-N); 6.1-
6.3:-<d. lH l'9!1 
Sb 0.88..0.95: (d, 3H CH); 0;65-2.1: (m. 9H cydoaL); 3.78-3.11; (s, 9H 30C11.s); 
3.8-4: (m. 1H CB-N); 6-6.1: (d. IH NB); 6.9-7: (s, 2H aromatics). 
Se: 0.85-0.95: (d, 3H CH,); 0.7-2.1: (m. 9H cydoaL); 3.&-4: (m. IH CB-N); 5.85-6: 
(d, IH NB); 6.38-6.5: (d. IH CO-CB=); 7.25-7.38: (m, 5H 1U"OIIIatic1); 7.58-
7.65:1d. IH =CH). 
5d 0.85-0.95: (d, 3H CH,); 0.75-2.1: (m. 9H cydoaL); 3.8-4: (m.lH CH-N); 5.6-
5.75: (d. 1H NB); 6,3-6,4: (d. IH CO-CB); 7.25-7,45: (m, 4H 1U"OIDatics); 7.5-
7.6: (d. IH CH=). 
Se: 0.85-0.95: (d, 3H Cn,); 0,70-2.1: (m. 9H cydoaL); 3.8-4: (s. 9H 3OCH,); 5.6-
5.75: (d. 1H NB); 6.25-6.35: (d, 1H ~ .. ); 6.7: (s, 2H al"Olllatics); 7.48-
7.53: (d, IH-cm. 
Sf 0.85-0.95: (d, 3H CH); 0.65-2.1: (m. 9HcydoaL); 3.85-4: (m. lH CH-N); 5.78-
5.86: (d. 1H NH)~ S.9-6.1: (5. 2H O-CR2-O)~ 6.18-6.3: (d, lH CO-CH"'); 6.7-7: 
l1~aromatics); 7.46-7.54: (d. IH=CH). 
6a 0.85-0.95: Cd, 3H cu,); 1-2.1: (m, 9H cydoaL); 3.8-3.98: (m,lH CH-N); 5.9-6: 
I (d, IH NR); 7.3.7.7: (m, 4H aromatics). . 
6b 0.8..0.9: (d. 3H CB,,); 1-2.1: (m, 9H cycloaL); 3.85: (s, 9HJOCH,,);3.75-3.95: 
I (m, lH CB-N); 5.95-6.05: (d 1H NR); 6.95: (s, 2H aromatics). 
6c 0.87-0.89: (d, 3H CB,); 1-2.1: (m. 9H cycloaL); 3.75-3.95: (d, IH CH-N); 5.65-
S.7S: (d, 1H NB); 6.35-6.4': (d, lH ~=); 7.3-7.5: (m, 5H aromatics); 7.'5-
7.65: (d, IH=CH). 
6d 0.88..0.91: (d, 3H CB,,); 1-2.1: (m, 9H c:ydoaL); 3.75-3.9: (m, IH CH-N); 5.45.-
S.5S: (d, IH NB); 6.3-6.35: (d, IH co-CB-); 7.25-7.45: (m. 4H aromatics); 
7.59-7.6: (d, IH =CIf). 
{le 0.85-0.9S: (d, 3H cu,); 1-2.1: (m. 9H cycloaL); 3.85: (s, 9HJOCHl ); 3.65-4: 
(m. lH CB-N); 5.65-S.75: (d. lH NB); 6.25-6.3S: (d, IH C~=); 6.72: (s, 2H 
aromatics}; 7.48-7.56: (d. IH=CB). 
6f 0.85..0.95: (d. 3H CH,,); 1-2.1: (m. 9H cydoaL); 3.75-3,9: (m, IH CB-N); 5.41-
S.71: (d, IH NB); 5.9: (s, 2H O-CR1-O); 6.1-6.2: (d. lH CO-CR=); 6.7-6.9: (m. 
3H aromatics); 7.4-7.5: (d. IH =CH). 
points were determined with a Kofler hot stage microscope 
and are uncorrected. 3-METHYLCYCLOHEX-2-ENONE. 7a 
IR spectra were recorded on a Perkin-Elmer mod. 298 spec-
trophotometer. including solid samples in KBr pellets and liq-
uid samples as films. The IH NMR measurements were per-
fonned on a Varian XL 200 Spectrometer, using CDCl) as 
solveni and tetramethyl silane (TMS) as internal standard. 
Chemical shifts (0) are expressed in p.p.m. downfield fromtet-
ramethylsilane. 
GC/MS spectra were obtained on a HP 5970A apparatus, 
equipped with a capillary column HP-5 (2SmxO.2 mmxO.ll 
J.lD1). Programmed temperature ranged from 100°C to 300 ·C 
(to ·C/min). detector temperature was set at 300·C and carrier 
gas was helium at 10 psi of pressure. 
Commercially available solvents and chemicals Were usually 
used for syntheses. 
It was ~repared by treating ethylacetoacetate. powdered par. 
aformaldehyde and piperidine according to the literaturelO. 
Physical and spectral data are reported in Table IV. 
3-METHYLCYCLOHEX-2-ENONE OXIME, 8a9 
13.8 g (0.199 mol) of hydroxylamine hydrochloride and 20.7 g 
(0.152 mol) of sodium acetate crystals (Na C2 H3 02·H20) were 
dissolved in 55 ml of water in two-necked round bottomed 
flask, fitted with a thermometer and a mechanical stirrer. 
The solution was then warmed up to about 40 ·C and 13.8 g 
(0.126 mol) of 3-methylcyclohex-2-enone were added. The mix-
ture was stirred for 30 min. White solid product was filtered 
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off and purified by recrystalllzation from hot water to give 8 .. 
(8.6 g. 55 %), rn.p. 48-50 QC. 
Physical.and spectral data are reported in Table N. 
3-METHYL- and 4-METHYLCYCLOHEXANONE OXIME, 
8b,e 
These compounds were, prenared by using the procedure 
already described by Lachman I: yields, m.p., IR spectral data 
are reported in Table N. 
3-METHYLCYCLOHEX-2-EN-I-AMINE, 9a7•8 
To a Solution of 3.36 g (0.027 mol) 3-methylcyclohex-2-enone 
oxime 8a, in. 56 ml of boiling anhydrous ethanol 6.5 g (0.283 
mol) of clean sodium (previously cut into small pieces) were 
added at a controlled rate for obtainihg that the reaction. 
although vigorous. remains under controL When sodium has 
reacted, the reaction mixture was cooled and diluted with 
aqueous ethanol solution (111) and then it was treated with 
concentrated hydrochloric acid. with stirring until the solution 
was acid to litmus. 
The white precipitate. in the cooled reaction mixture, was 
filtered off and the solvent evaporated under vacuum to leave a 
viscous oil, which was washed with diethyl ether discarding 
the ether layer. The aqueous layer was basified with 2N NaOH 
solution and extracted with diethyl ether which was dried with 
anhydrous sodium sulfate, and evaporated under vacuum to 
leave a oily residue. The crude oil was distilled on a Kugelrohr 
apparatus under vacuum (bp 45-65 QC, 0.5 mm Hg) to yield 
, 1.76 g (59%) of the 3-methylcyclohex-2-en-t-amine 9a, as a 
dear liquid (Table N). 
TABLE IV - Characteristics of intermediate products 
m.p or 
Comp. MW b.pJ(mrn Hg) 
·C 
7a 110 95/25 
la 125 48-50 
'b 127 110-116115 
ac 127 90-10015 
9a 111 45-6SfO.5 
9b 113 50-70110,·4, 
9c 113 50-70110'0<' 
(12) Lit: 151 °Cn30mmHg. 
(12) Lit: 148 °cn17 mmHg. 
Yield IR (errr1) 
'lIo 
44 1680 (vC=O) 
55 3240(v 0Hl: 1700{v C=N) 
93 3260fv OH): 165O(v C=N) 
85 3210(v OH); 169O(vC=N) 
59 3340-3280{v NfW:1570{v NHU 
62 332O-326O(v NHV;1580(v NHU 
70 3320-3260{v NHV;1580(vNHV 
3-METHYL- AND4-METHYL-CYCLOHEXYLAMINE, 9b,e 
Compounds 9b.c were prepared as reported for derivative 
9a. starting from the suitable J-methyl- and 4-methyl-
cydohexanone oxime 8b,C7,8, 
Physical analytical and spectroscopic data are reported in 
TableN. 
N-AROYLCYCLOHEXYL- AND N-AROYLCYCLOHE-
XENYL-AMIDES 3 OR 4 MONOSUBSTITUTED, 4a-f, 
Sa-f AND 6a-f 
The appropriate amine (5 mmol), dissolved in anhydrous 
benzene (30 ml), was dropwise added to a solution of acyl 
chloride (a stoichiometric quantity, increased of 10-2ooM and 
stirred in the same solvent (10-15 ml). 
The mixture was stirred at room temperature for a time var· 
ying from 30 minutes to 2 hours; at this time. the reaction was 
considered completed. after having monitored the disappear-
ance of starting materials by TLC analysis (benzene-acetone 
8:2 vlv eluant). It was filtered and the benzene solution was 
shaken with a solution of NaHCOJ (5%) and subsequently with 
water. After benzene removal. pure compounds were obtained 
generally by crystallization of the residue from alcohol or 
TABLE V - Carrageenan rat paw edema: anti-
inflanimatory activity 
Compound Dose " Edema inhibition relative to control at: 
(mglkgpo) S"h ED50 (mg/kg) ,j"h ED50 (mgIkg) 
Indomethacin 5 -63 -68 
<la 40 -22 -17 
40 -61 -67 
4b 20 -50 24.4 -56 18.5 
10 ~24 (19.5-30.6) -33 (14.4-23.7) 
40 ·46 -54 
Ok 20 -28 ·37 33.9 
10 -10 -21 (26.6-43.3) 
4d 40 -13 - 7 
4e 40 .17 -30 
5a 40 -22 -15 
.fib 40 -44 -38 
Se 40 -14 -10 
fid 40 -<f8 ·42 
Se 40 -30 -38 
40 -82 -84 
Sa 20 -46 20.9 -53 17.7 
10 -16 (18.1-24.1) ·26 (15.5-20.3) 
40 -58 -64 
6b 20 -34 31.8 ·26 31.2 
10 
- 8 (26.9-37.6) - 7 (26.9-36.1) 
le: 40 -45 -37 
6d 40 -33 -29 
Sa 40 -33 -29 
Sf 40 -17 -14 
TABLE VI 
-
Acetic acid writhing test: analgesic 
activity 
Compound Dose Mean No of writhes in "Decrease 
(mgI/<g po) 25 min period after relative to controls 
treatment:l: SE 
Control. 47.3±4.1 
indomethacin 5 23.0±3.9 -51 
4a 40 31.3±3.8 -34 
4b 40 24,9 ± 4.2 -47 
4c 40 26.1 ±2.8 -45 
4d 40 39.6±5.1 -16 
4e 40 36.7 ± 3.7 -22 
Sa 40 33.8 ± 5.2 -28 
Sb 40 35.7±3.6 -:24 
Se 40 38.6±4.1 -18 
5d 40 37.1 ±2.8 -22 
Se 40 41.3±2.8 -13 
Sa 40 25.1 ±3.3 -47 
6b 40 41.2±4.5 -13 
Se 40 35,8±2.9 -24 
6d 40 29,7±5.1 -37 
6e 40 37.S±4,2 - 21 
6f 40 36.7 ± 4.3 -22 
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TABLE vn - Induction of gastric lesions in rats 
Compound Dose t!' h after treatment. animals with: 
(mglkgpo) 
Hyperaemia (%) Ulcers (%J 
Indomethacin 5 80 60 
4a 100 60 30 
4b 100 50 40 
4c 100 70 50 
4d 100 40 20 
4e 100 80 20 
sa 100 20 20 
5b 100 50 30 
Se 100 30 20 
5d 100 60 40 
Se 100 50 40 
Sa 100 50 30 
$I) 100 40 30 
Se 100 :,0 20 
6d 100 40 20 
6e 100 60 30 
6f 100 30 30 
hydro-alcoholic mixture. For a complete purification. whereas 
in some cases a chromatography on silica gel column with 
benzene-acetone 8:2 as eluant Was necessary, in other cases a 
Flash chromatography was carried out using silica gel 60 
(Merck 230400 mesh ASTM). The appropriate fractions were 
collected and evaporated to yield the desired products (table I). 
All compounds exhibited IR, GC/Mass, and IH NMR spectra 
consistent with those of the structures assigned (Tables n and ID). 
B) PHARMACOLOGY 
Tested compounds were administered orally by gavage in 1% 
methylcellulose suspension, using first a dose of 40 mglkg and 
then lower doses if a significant activity was found. 
Gastric ulcerogeniC action was studied in rats which were 
treated orally with high doses (lOO mglkg). 
Indomethacin was included in all tests for comparison pur-
poses at the dose level of 5 mglkg. 
The following experimental PI'QCedures were employed: 
ANTl~INFLAMMATORY ACTIVITY 
Paw edema inhibition testJ4 was used on rats. Groups of 5 
rats of both sexes (body weight t 80-250 g), pregnant females 
excluded. were given a dose of a test compound. Thirty min 
later 0.2 ml of 1% carrageenan suspension in O.90Al NaCI .solu-
lion was injected subcutaneously into the plantar aponeurosis 
of the hind paw. The paw volume was measured by a water ple-
thysmometer Socrel and then measured again 1, 2. 3, 4 h later. 
The mean increase of paw volume at each time interval was 
compared with that of the control group (5 rats treated with 
carrageenan, but not treated with test compounds) at the same 
time intervals and percent inhibition values were calculated. 
Experimental resUlts at yd and 4th hours are listed in Table V. 
ANALGESIC ACTIVITY 
Acetic acid writhing teses was used on mice. Groups. of 5 
mice (body weight 20-30 g) of both sexes, pregnant. females 
excluded. were given a dose of a test compound. ThirIy min 
later the animals were injectedintraperitoneaUy with 0;25 
mlImouse of 0.5% acetic acid solution and writhes were coun-
ted during the following 25 min. The mean number of writhes 
for each experimental group and percent decrease compared 
with the control group (5 mice not treated with test com-
pounds) were calculated. Experimental results are listed in 
Table VI. 
ULCEROGENIC ACTION 
Groups of 10 rats (body weight 180-250 g) of both sexes, 
pregnant females excluded, were treated with an oral dose of a 
test compound, except the control groUp/6. All animals were 
sacrificed 6 h after dosing and their stomachs and small intes-
tines were examined using a 2><2 binocular magnifier, to assess 
the incidence of hyperemia and ulcers. All the ulcers >0.5 mm 
were recorded. Experimental results are listed in Table VU. 
This work was partially supported by M.U.R.S.T. 
(60 %). 
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